FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2786016821> ?p ?o ?g. }

• W2786016821 endingPage "309" @default.
• W2786016821 startingPage "299" @default.
• W2786016821 abstract "Background Standard treatment for thyroid eye disease is with systemic corticosteroids. We aimed to establish whether orbital radiotherapy or antiproliferative immunosuppression would confer any additional benefit. Methods CIRTED was a multicentre, double-blind, randomised controlled trial with a 2 × 2 factorial design done at six centres in the UK. Adults with active moderate-to-severe thyroid eye disease associated with proptosis or ocular motility restriction were recruited to the trial. Patients all received a 24 week course of oral prednisolone (80 mg per day, reduced to 20 mg per day by 6 weeks, 10 mg per day by 15 weeks, and 5 mg per day by 21 weeks) and were randomly assigned via remote computerised randomisation to receive either radiotherapy or sham radiotherapy and azathioprine or placebo in a 2 × 2 factorial design. Randomisation included minimisation to reduce baseline disparities in potential confounding variables between trial interventions. Patients and data analysts were masked to assignment, whereas trial coordinators (who monitored blood results), pharmacists, and radiographers were not. The radiotherapy dose was 20 Gy administered to the retrobulbar orbit in ten to 12 fractions over 2 to 3 weeks. Azathioprine treatment was provided for 48 weeks at 100–200 mg per day (dispensed as 50 mg tablets), depending on bodyweight (100 mg for <50 kg, 150 mg 50–79 kg, 200 mg for ≥80 kg). The primary outcomes were a binary composite clinical outcome score and an ophthalmopathy index at 48 weeks, and a clinical activity score at 12 weeks. The primary analysis was based on the intention-to-treat allocation and safety was assessed in all participants. This study is registered with ISRCTN, number 22471573. Findings Between Feb 15, 2006, and Oct 3, 2013, 126 patients were recruited and randomly assigned to groups: 31 patients to radiotherapy plus azathioprine, 31 to sham radiotherapy and azathioprine, 32 to radiotherapy and placebo, and 32 to sham radiotherapy and placebo. Outcome data were available for 103 patients (54 for sham radiotherapy vs 49 for radiotherapy and 53 for placebo vs 50 for azathioprine), of whom 84 completed their allocated treatment of radiotherapy or sham radiotherapy and 57 continued to take azathioprine or placebo up to 48 weeks. There was no interaction betweeen azathioprine and radiotherapy (pinteraction=0·86). The adjusted odds ratio (ORadj) for improvement in the binary clinical composite outcome measure was 2·56 (95% CI 0·98–6·66, p=0·054) for azathioprine and 0·89 (0·36–2·23, p=0·80) for radiotherapy. In a post-hoc analysis of patients who completed their allocated therapy the ORadj for improvement was 6·83 (1·66–28·1, p=0·008) for azathioprine and 1·32 (0·30–4·84, p=0·67) for radiotherapy. The ophthalmopathy index, clinical activity score, and numbers of adverse events (161 with azathioprine and 156 with radiotherapy) did not differ between treatment groups. In both groups, the most common adverse events were mild infections. No patients died during the study. Interpretation In patients receiving oral prednisolone for 24 weeks, radiotherapy did not have added benefit. We also did not find added benefit for addition of azathioprine in the primary analysis; however, our conclusions are limited by the high number of patients who withdrew from treatment. Results of post-hoc analysis of those who completed the assigned treatment suggest improved clinical outcome at 48 weeks with azathioprine treatment. Funding National Eye Research Centre, Above and Beyond, and Moorfields Eye Charity. Standard treatment for thyroid eye disease is with systemic corticosteroids. We aimed to establish whether orbital radiotherapy or antiproliferative immunosuppression would confer any additional benefit. CIRTED was a multicentre, double-blind, randomised controlled trial with a 2 × 2 factorial design done at six centres in the UK. Adults with active moderate-to-severe thyroid eye disease associated with proptosis or ocular motility restriction were recruited to the trial. Patients all received a 24 week course of oral prednisolone (80 mg per day, reduced to 20 mg per day by 6 weeks, 10 mg per day by 15 weeks, and 5 mg per day by 21 weeks) and were randomly assigned via remote computerised randomisation to receive either radiotherapy or sham radiotherapy and azathioprine or placebo in a 2 × 2 factorial design. Randomisation included minimisation to reduce baseline disparities in potential confounding variables between trial interventions. Patients and data analysts were masked to assignment, whereas trial coordinators (who monitored blood results), pharmacists, and radiographers were not. The radiotherapy dose was 20 Gy administered to the retrobulbar orbit in ten to 12 fractions over 2 to 3 weeks. Azathioprine treatment was provided for 48 weeks at 100–200 mg per day (dispensed as 50 mg tablets), depending on bodyweight (100 mg for <50 kg, 150 mg 50–79 kg, 200 mg for ≥80 kg). The primary outcomes were a binary composite clinical outcome score and an ophthalmopathy index at 48 weeks, and a clinical activity score at 12 weeks. The primary analysis was based on the intention-to-treat allocation and safety was assessed in all participants. This study is registered with ISRCTN, number 22471573. Between Feb 15, 2006, and Oct 3, 2013, 126 patients were recruited and randomly assigned to groups: 31 patients to radiotherapy plus azathioprine, 31 to sham radiotherapy and azathioprine, 32 to radiotherapy and placebo, and 32 to sham radiotherapy and placebo. Outcome data were available for 103 patients (54 for sham radiotherapy vs 49 for radiotherapy and 53 for placebo vs 50 for azathioprine), of whom 84 completed their allocated treatment of radiotherapy or sham radiotherapy and 57 continued to take azathioprine or placebo up to 48 weeks. There was no interaction betweeen azathioprine and radiotherapy (pinteraction=0·86). The adjusted odds ratio (ORadj) for improvement in the binary clinical composite outcome measure was 2·56 (95% CI 0·98–6·66, p=0·054) for azathioprine and 0·89 (0·36–2·23, p=0·80) for radiotherapy. In a post-hoc analysis of patients who completed their allocated therapy the ORadj for improvement was 6·83 (1·66–28·1, p=0·008) for azathioprine and 1·32 (0·30–4·84, p=0·67) for radiotherapy. The ophthalmopathy index, clinical activity score, and numbers of adverse events (161 with azathioprine and 156 with radiotherapy) did not differ between treatment groups. In both groups, the most common adverse events were mild infections. No patients died during the study. In patients receiving oral prednisolone for 24 weeks, radiotherapy did not have added benefit. We also did not find added benefit for addition of azathioprine in the primary analysis; however, our conclusions are limited by the high number of patients who withdrew from treatment. Results of post-hoc analysis of those who completed the assigned treatment suggest improved clinical outcome at 48 weeks with azathioprine treatment." @default.
• W2786016821 created "2018-02-23" @default.
• W2786016821 creator A5001070888 @default.
• W2786016821 creator A5003294946 @default.
• W2786016821 creator A5003605083 @default.
• W2786016821 creator A5005259325 @default.
• W2786016821 creator A5010213726 @default.
• W2786016821 creator A5013438524 @default.
• W2786016821 creator A5016660698 @default.
• W2786016821 creator A5017507233 @default.
• W2786016821 creator A5019117494 @default.
• W2786016821 creator A5020690169 @default.
• W2786016821 creator A5021263113 @default.
• W2786016821 creator A5023348562 @default.
• W2786016821 creator A5029898835 @default.
• W2786016821 creator A5039399425 @default.
• W2786016821 creator A5041895402 @default.
• W2786016821 creator A5043196932 @default.
• W2786016821 creator A5045428660 @default.
• W2786016821 creator A5046387225 @default.
• W2786016821 creator A5049951818 @default.
• W2786016821 creator A5056226637 @default.
• W2786016821 creator A5056293873 @default.
• W2786016821 creator A5057195015 @default.
• W2786016821 creator A5060031439 @default.
• W2786016821 creator A5063644249 @default.
• W2786016821 creator A5063975158 @default.
• W2786016821 creator A5069032977 @default.
• W2786016821 creator A5071458956 @default.
• W2786016821 creator A5071801633 @default.
• W2786016821 creator A5075357049 @default.
• W2786016821 creator A5079869720 @default.
• W2786016821 creator A5080271894 @default.
• W2786016821 creator A5085337143 @default.
• W2786016821 creator A5085525375 @default.
• W2786016821 creator A5087936326 @default.
• W2786016821 creator A5089717198 @default.
• W2786016821 date "2018-04-01" @default.
• W2786016821 modified "2023-10-03" @default.
• W2786016821 title "Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial" @default.
• W2786016821 cites W1987200661 @default.
• W2786016821 cites W2023660047 @default.
• W2786016821 cites W2038106393 @default.
• W2786016821 cites W2061431159 @default.
• W2786016821 cites W2066663435 @default.
• W2786016821 cites W2077771027 @default.
• W2786016821 cites W2088135214 @default.
• W2786016821 cites W2094900930 @default.
• W2786016821 cites W2099402970 @default.
• W2786016821 cites W2131969862 @default.
• W2786016821 cites W2138922798 @default.
• W2786016821 cites W2139030289 @default.
• W2786016821 cites W2141817617 @default.
• W2786016821 cites W2142388081 @default.
• W2786016821 cites W2152080639 @default.
• W2786016821 cites W2154787313 @default.
• W2786016821 cites W2158064334 @default.
• W2786016821 cites W2288910126 @default.
• W2786016821 cites W2324861642 @default.
• W2786016821 cites W2334870842 @default.
• W2786016821 cites W2342675325 @default.
• W2786016821 cites W2461126386 @default.
• W2786016821 cites W2611131029 @default.
• W2786016821 doi "https://doi.org/10.1016/s2213-8587(18)30021-4" @default.
• W2786016821 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29396245" @default.
• W2786016821 hasPublicationYear "2018" @default.
• W2786016821 type Work @default.
• W2786016821 sameAs 2786016821 @default.
• W2786016821 citedByCount "59" @default.
• W2786016821 countsByYear W27860168212018 @default.
• W2786016821 countsByYear W27860168212019 @default.
• W2786016821 countsByYear W27860168212020 @default.
• W2786016821 countsByYear W27860168212021 @default.
• W2786016821 countsByYear W27860168212022 @default.
• W2786016821 countsByYear W27860168212023 @default.
• W2786016821 crossrefType "journal-article" @default.
• W2786016821 hasAuthorship W2786016821A5001070888 @default.
• W2786016821 hasAuthorship W2786016821A5003294946 @default.
• W2786016821 hasAuthorship W2786016821A5003605083 @default.
• W2786016821 hasAuthorship W2786016821A5005259325 @default.
• W2786016821 hasAuthorship W2786016821A5010213726 @default.
• W2786016821 hasAuthorship W2786016821A5013438524 @default.
• W2786016821 hasAuthorship W2786016821A5016660698 @default.
• W2786016821 hasAuthorship W2786016821A5017507233 @default.
• W2786016821 hasAuthorship W2786016821A5019117494 @default.
• W2786016821 hasAuthorship W2786016821A5020690169 @default.
• W2786016821 hasAuthorship W2786016821A5021263113 @default.
• W2786016821 hasAuthorship W2786016821A5023348562 @default.
• W2786016821 hasAuthorship W2786016821A5029898835 @default.
• W2786016821 hasAuthorship W2786016821A5039399425 @default.
• W2786016821 hasAuthorship W2786016821A5041895402 @default.
• W2786016821 hasAuthorship W2786016821A5043196932 @default.
• W2786016821 hasAuthorship W2786016821A5045428660 @default.
• W2786016821 hasAuthorship W2786016821A5046387225 @default.
• W2786016821 hasAuthorship W2786016821A5049951818 @default.
• W2786016821 hasAuthorship W2786016821A5056226637 @default.
• W2786016821 hasAuthorship W2786016821A5056293873 @default.
• W2786016821 hasAuthorship W2786016821A5057195015 @default.

• next